Photo of Andrius Kazlauskas,  PhD

Andrius Kazlauskas, PhD

Schepens Eye Research Institute

Schepens Eye Research Institute
Phone: (617) 912-2517
Fax: (617) 912-0101

Andrius Kazlauskas, PhD

Schepens Eye Research Institute


  • Professor, Ophthalmology, Harvard Medical School
  • Senior Scientist, SERI, Schepens Eye Research Institute

Research Abstract

I am a basic scientist who devotes the majority (90%) of his time and attention to investigating intracellular signaling pathways that govern cellular responses. The resulting insights are used to advance our understanding of pathology, and to develop new therapeutic options for patients afflicted by disease. Intrinsic to this type of undertaking is the training of postdoctoral fellows, graduate students and clinical fellows. The remainder of my time (10%) is devoted to administrative activities and traditional (classroom-based) teaching of graduate and undergraduate students.

My laboratory is contributing to two research areas: intracellular signaling events that govern angiogenesis, and the role of growth factors in human disease. The angiogenesis projects are developing from our recent discovery of an internal destabilization pathway that controls the stability of blood vessels. We are identifying essential components of this pathway, and assessing their role in the pathogenesis of endemic, blinding conditions such as proliferative diabetic retinopathy and neovascular age-related macular degeneration. The growth factor projects emanate from our surprising observation that a non-traditional route to activate growth factor receptors is particularly important for the appearance of pathology. These findings have provided new opportunities to develop effective therapeutic strategies and thereby improve health care and the quality of life for patients.

In summary, the overall goal of my research is to elucidate the principles by which intracellular signaling controls the behavior of cells, and thereby provide the conceptual foundation for development of improved therapeutic options, especially in the field of ophthalmology.


Powered by Harvard Catalyst
  • Strainiene E, Binkis M, Urnikyte S, Stankevicius V, Sasnauskiene A, Kundrotas G, Kazlauskas A, Suziedelis K. Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines. BMC Cancer 2018; 18:222. PubMed
  • Kazlauskas A. PDGFs and their receptors. Gene 2017; 614:1-7. PubMed
  • Ma G, Duan Y, Huang X, Qian CX, Chee Y, Mukai S, Cui J, Samad A, Matsubara JA, Kazlauskas A, D'Amore PA, Gu S, Lei H. Prevention of Proliferative Vitreoretinopathy by Suppression of Phosphatidylinositol 5-Phosphate 4-Kinases. Invest Ophthalmol Vis Sci 2016; 57:3935-43. PubMed
  • Pennock S, Kim LA, Kazlauskas A. VEGF-A acts via PDGFRα to promote viability of cells enduring hypoxia. Mol Cell Biol 2016. PubMed
  • Lei H, Qian CX, Lei J, Haddock LJ, Mukai S, Kazlauskas A. RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology. Mol Cell Biol 2015. PubMed
  • Kazlauskas A. Lysophosphatidic acid contributes to angiogenic homeostasis. Exp Cell Res 2015. PubMed
  • Jacobo SM, Kazlauskas A. Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels. J Biol Chem 2015; 290:6349-60. PubMed
  • Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 2014; 40C:16-34. PubMed
  • Lei H, Kazlauskas A. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α. Mol Cell Biol 2013; 34:110-22. PubMed
  • Ruan GX, Kazlauskas A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem 2013; 288:21161-72. PubMed
  • Ruan GX, Kazlauskas A. VEGF-A engages at least three tyrosine kinases to activate PI3K/Akt. Cell Cycle 2012; 11:2047-8. PubMed
  • Lei H, Velez G, Kazlauskas A. Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53. Mol Cell Biol 2011. PubMed
  • Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A. The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Res 2010; 70:4195-203. PubMed
  • Im E, Motiejunaite R, Aranda J, Park EY, Federico L, Kim TI, Clair T, Stracke ML, Smyth S, Kazlauskas A. PLC{gamma} activation drives increased production of autotaxin in endothelial cells and LPA-dependent regression. Mol Cell Biol 2010; 30:2401-10. PubMed
  • Lei H, Rheaume MA, Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 2010; 90:376-81. PubMed
  • Lei H, Kazlauskas A. Focus on Molecules: Platelet-derived growth factor C, PDGF-C. Exp Eye Res 2007; 86:711-2. PubMed
  • Romeo GR, Kazlauskas A. Oxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1. J Biol Chem 2008; 283:9595-605. PubMed
  • Motiejunaite R, Kazlauskas A. Pericytes and ocular diseases. Exp Eye Res 2007; 86:171-7. PubMed
  • Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2008; 49:42-8. PubMed
  • Im E, Kazlauskas A. Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 2007; 282:29122-9. PubMed
  • Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 2007; 7:2082-9. PubMed
  • Romeo GR, Moulton KS, Kazlauskas A. Attenuated expression of profilin-1 confers protection from atherosclerosis in the LDL receptor null mouse. Circ Res 2007; 101:357-67. PubMed
  • Im E, Kazlauskas A. PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis. Expert Opin Ther Targets 2007; 11:443-51. PubMed
  • Im E, Kazlauskas A. New insights regarding vessel regression. Cell Cycle 2006; 5:2057-9. PubMed
  • Im E, Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P2. EMBO J 2006; 25:2075-82. PubMed